Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
Wegovy Launches in Malaysia: Competition for Gym Memberships - Featured image
GLP-1 Medications

Wegovy Launches in Malaysia: Competition for Gym Memberships

Shotlee Editorial Team
Written by Shotlee Editorial TeamHealth Research & Writing
·January 15, 2026·2 min read

On this page

  • Malaysia's Growing Obesity Challenge
  • How Wegovy Works
  • Expert Insights on Obesity Treatment
  • Novo Nordisk's Commitment
  • Obesity's Link to Heart Disease

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

Novo Nordisk's Wegovy is now available in Malaysia, offering a powerful GLP-1 option for adults with obesity or overweight conditions. With 54.4% of Malaysian adults affected, this once-weekly injection mimics gut hormones to regulate appetite. Medical experts emphasize combining it with diet, exercise, and lifestyle changes for optimal results.

Share

On this page

  • Malaysia's Growing Obesity Challenge
  • How Wegovy Works
  • Expert Insights on Obesity Treatment
  • Novo Nordisk's Commitment
  • Obesity's Link to Heart Disease

Novo Nordisk has launched Wegovy (semaglutide 2.4mg) in Malaysia, providing a new treatment for adults with obesity or overweight plus related health issues. This GLP-1 medication arrives as the country faces a mounting obesity crisis.

Malaysia's Growing Obesity Challenge

The National Health and Morbidity Survey (NHMS) 2023 shows that 54.4% of Malaysian adults are overweight or living with obesity. This epidemic underscores the need for effective interventions beyond traditional methods like gym memberships.

How Wegovy Works

Wegovy is a once-weekly injectable that mimics the natural gut hormone GLP-1. It targets brain areas to reduce hunger and cravings, promoting weight loss when paired with a reduced-calorie diet and increased physical activity.

Expert Insights on Obesity Treatment

Medical professionals praise the launch, viewing obesity as a complex disease influenced by biology, behavior, and environment.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Get it onGoogle Play
"Obesity is a biological, behavioural, and environmental condition, and not simply the result of lack of discipline," said Professor Dr Rohana Abdul Ghani, President of the Malaysian Obesity Society.

She noted that stigma creates emotional barriers to weight management.

Endocrinologist Emeritus Professor Dr Chan Siew Pheng advocates a holistic approach: "By integrating medication with personalised dietary and lifestyle interventions, we can significantly improve patient outcomes." The body's metabolism often fights weight loss, making such combinations essential.

Obesity's Link to Heart Disease

Datuk Seri Dr Azhari Rosman, a senior consultant cardiologist, warns that obesity is a major risk factor for heart disease. Effective management is crucial for overall health.

Novo Nordisk's Commitment

Dr Praful Chakkarwar, General Manager of Novo Nordisk Malaysia, calls the launch a "pivotal moment." It supports local clinical research and public health initiatives to transform obesity care. Apps like Shotlee can help track weekly Wegovy doses for better adherence.

Source Information

Originally published by Malay Mail.Read the original article →

Read next

Keep exploring

More on Wegovy

Articles covering Wegovy dosing, side effects, and clinical updates.

What's the Deal with Peptides? The Hyped Market Under FDA Review
Health & Wellness

What's the Deal with Peptides? The Hyped Market Under FDA Review

An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.

8 min read
Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program
Health & Wellness

Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program

Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.

8 min read
Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials
Medical Research

Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials

Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.

7 min read

Same topic: Wegovy

All Wegovy articles →
Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics
Pharmaceutical Industry News

Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics

Samsung Biologics has announced a major acquisition of PolyPeptide Group AG for $1.8 billion, marking a strategic expansion into the rapidly growing peptide therapeutics market, particularly for GLP-1 drugs.

8 min read

More in GLP-1 Medications

Specialist: Funding Wegovy Saves Taxpayer Money Long-Term
GLP-1 Medications

Specialist: Funding Wegovy Saves Taxpayer Money Long-Term

Pharmac is evaluating funding for Wegovy, a GLP-1 receptor agonist, to combat New Zealand's high obesity rates. Weight loss specialist Dr. Gerard McQuinlan says it could save taxpayers billions by preventing diseases like Type 2 diabetes. Experts weigh long-term costs, side effects, and criteria.

2 min read
Pharmac Seeks Advice on Funding Wegovy Weight Loss Drug
GLP-1 Medications

Pharmac Seeks Advice on Funding Wegovy Weight Loss Drug

New Zealand faces the third-highest adult obesity rate in the OECD, prompting Pharmac to seek clinical advice on funding Wegovy. Two applications propose semaglutide for high-BMI patients with cardiovascular risks or comorbidities. Experts argue it could save billions by preventing diseases like Type 2 diabetes.

2 min read
Prof Urges Caution on Funding Wegovy Rollout
GLP-1 Medications

Prof Urges Caution on Funding Wegovy Rollout

Prof Jim Mann cautions against broad funding for Wegovy, urging focus on high-risk patients like those with heart disease or diabetes. He emphasizes integrating GLP-1 medications into a national obesity strategy with mandatory nutritional support to prevent weight regain. Early data highlights side effect risks and the need for dietary counseling.

2 min read
Share this article
  1. Home
  2. Blog
  3. Wegovy Launches in Malaysia: Competition for Gym Memberships
Shotlee Editorial Team — Health Research & Writing
Written by

Shotlee Editorial Team

Health Research & Writing

Shotlee’s guides and articles are researched and written in-house by the Shotlee Editorial Team. We build every page from primary sources — FDA labels, official prescribing information, and peer-reviewed clinical trials — and cite them directly. Our content is educational and is not a substitute for advice from your own healthcare provider.

View all articles by Shotlee Editorial Team
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community